Cohance Lifesciences Limited vs Wockhardt Limited
Last updated: 28 October 2026
MoneyDock presents a comparative analysis between Cohance Lifesciences Limited and Wockhardt Limited, two prominent players in the Indian pharmaceutical sector. While both companies operate within the broad healthcare industry, they often cater to different segments or have varying market strategies, making a direct comparison intriguing for investors looking at the pharma space. Cohance Lifesciences, trading under COHANCE.NS, and Wockhardt Limited, listed as WOCKPHARMA.NS, represent different investment profiles as we delve into their recent market performance and valuation metrics. This analysis aims to shed light on their respective strengths and weaknesses based purely on the provided financial data, helping investors make informed decisions.
Key Financial Metrics Comparison
| Metric | Cohance Lifesciences (COHANCE.NS) | Wockhardt Limited (WOCKPHARMA.NS) |
|---|---|---|
| Current Price | ₹479.25 | ₹1884.80 |
| 52-Week High | ₹539.85 | ₹2329.70 |
| 52-Week Low | ₹279.90 | ₹1100.30 |
| 1-Year Return | -10.99% | 33.57% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Who Wins?
Valuation: Unfortunately, a direct comparison on valuation metrics like Trailing P/E and Market Cap is not possible as the data for both Cohance Lifesciences and Wockhardt Limited is unavailable ('N/A'). This limits our ability to gauge how the market values their earnings or their overall size. Investors would need to seek additional fundamental data to make a comprehensive valuation assessment.
Returns: In terms of 1-Year Returns, Wockhardt Limited clearly outperforms Cohance Lifesciences. Wockhardt has delivered a robust 33.57% return over the past year, indicating strong positive momentum and investor confidence. In contrast, Cohance Lifesciences has seen a negative return of -10.99% over the same period, suggesting underperformance or market headwinds. For investors prioritizing recent performance, Wockhardt appears to be the stronger contender.
Stability: To assess stability, we can look at the relation between the current price and the 52-week high and low. Cohance Lifesciences' current price of ₹479.25 is closer to its 52-week high of ₹539.85 than its 52-week low of ₹279.90. This suggests it has maintained a relatively higher level within its annual range. Wockhardt Limited, with a current price of ₹1884.80, is also closer to its 52-week high of ₹2329.70 than its 52-week low of ₹1100.30. Both stocks have traded above their 52-week lows, indicating some level of resilience. However, the significantly positive 1-year return for Wockhardt might suggest greater underlying business stability or growth driving that performance, relative to Cohance's negative return.
Overall, based on the provided metrics, Wockhardt Limited appears to be the stronger performer in terms of recent returns. However, the absence of crucial valuation metrics like P/E and Market Cap means investors must exercise caution and conduct further research before making any final decisions.
MoneyDock Verdict
For Aggressive Investors: Wockhardt Limited (WOCKPHARMA.NS) might be more appealing due to its significant 1-year return of 33.57%, signaling strong momentum. However, the lack of P/E and Market Cap data necessitates high-risk tolerance and thorough independent research into its fundamentals before investment.
For Conservative Investors: Neither stock offers sufficient data (e.g., Trailing P/E, Market Cap) for a truly conservative assessment based solely on these numbers. The negative 1-year return for Cohance Lifesciences might deter conservative investors, while Wockhardt's strong return without valuation context still presents an unknown risk. Caution is advised, and further due diligence is essential.
For Long-term SIP Investors: Given the limited data, particularly the absence of valuation metrics and market capitalization, making a definitive long-term SIP recommendation is challenging. Wockhardt's positive one-year performance is encouraging, but without insight into its underlying value or size, it's hard to gauge its long-term potential or stability. Cohance's negative return could signal a potential recovery play for long-term investors if future fundamentals improve, but this would be a speculative bet. Both require deeper fundamental analysis beyond these figures for long-term commitment.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.